Abstract
Purpose: We determined whether the novel nuclear factor κB activation inhibitor dehydroxymethylepoxyquinomicin (DHMEQ), which is derived from epoxyquinomicin C, affects renal inflammatory responses in unilateral ureteral obstruction. Materials and Methods: DHMEQ (8 mg./kg.) was administered to rats 1 day after unilateral ureteral obstruction and every day thereafter. Kidneys were harvested at day 7 after unilateral ureteral obstruction. Tissue nuclear factor κB activity and transforming growth factor-β were determined by electrophoretic mobility shift assay and bioassay using mink lung epithelial cells, respectively. Renal tubular proliferation and apoptosis were detected by immunostaining proliferating cellular nuclear antigen and the TUNEL (Intergen, Purchase, New York) assay, respectively. Leukocyte infiltration was detected by immunostaining for CD45. Fibrosis was assessed by measuring tissue hydroxyproline content. Results: Unilateral ureteral obstruction for 7 days significantly activated nuclear factor κB, induced tubular apoptosis, proliferation and interstitial fibrosis in the obstructed kidney of the control group compared with their unobstructed counterparts (30.3 ± 4.5 nuclei per high power field versus 1.7 ± 0.4, 25.7 ± 3.3 nuclei per high power field versus 3.2 ± 0.4 and 6.2 ± 0.3 μmol. hydroxyproline per gm. tissue versus 3.4 ± 0.1, respectively). Conversely daily administration of DHMEQ (8 mg./kg.) significantly inhibited nuclear factor κB activation and decreased mean tubular apoptosis (9.5 ± 2.1 nuclei per high power field), proliferation (10.2 ± 2.4 nuclei per high power field) and interstitial fibrosis (4.9 ± 0.4 μmol. hydroxyproline per gm. tissue) in the obstructed kidney. Conclusions: Specific inhibition of nuclear factor κB can prevent inflammatory renal responses, suggesting that targeting nuclear factor κB activation may be feasible for preventing inflammatory kidney diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 1559-1563 |
| Number of pages | 5 |
| Journal | Journal of Urology |
| Volume | 169 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2003 Apr 1 |
| Externally published | Yes |
Fingerprint
Keywords
- Apoptosis
- Inflammation
- Kidney
- Transcription factors
- Ureteral obstruction
ASJC Scopus subject areas
- Urology
Cite this
Novel nuclear factor κB activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. / Miyajima, Akira; Kosaka, Takeo; Seta, Kaori; Asano, Tomohiko; Umezawa, Kazuo; Hayakawa, Masamichi.
In: Journal of Urology, Vol. 169, No. 4, 01.04.2003, p. 1559-1563.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Novel nuclear factor κB activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction
AU - Miyajima, Akira
AU - Kosaka, Takeo
AU - Seta, Kaori
AU - Asano, Tomohiko
AU - Umezawa, Kazuo
AU - Hayakawa, Masamichi
PY - 2003/4/1
Y1 - 2003/4/1
N2 - Purpose: We determined whether the novel nuclear factor κB activation inhibitor dehydroxymethylepoxyquinomicin (DHMEQ), which is derived from epoxyquinomicin C, affects renal inflammatory responses in unilateral ureteral obstruction. Materials and Methods: DHMEQ (8 mg./kg.) was administered to rats 1 day after unilateral ureteral obstruction and every day thereafter. Kidneys were harvested at day 7 after unilateral ureteral obstruction. Tissue nuclear factor κB activity and transforming growth factor-β were determined by electrophoretic mobility shift assay and bioassay using mink lung epithelial cells, respectively. Renal tubular proliferation and apoptosis were detected by immunostaining proliferating cellular nuclear antigen and the TUNEL (Intergen, Purchase, New York) assay, respectively. Leukocyte infiltration was detected by immunostaining for CD45. Fibrosis was assessed by measuring tissue hydroxyproline content. Results: Unilateral ureteral obstruction for 7 days significantly activated nuclear factor κB, induced tubular apoptosis, proliferation and interstitial fibrosis in the obstructed kidney of the control group compared with their unobstructed counterparts (30.3 ± 4.5 nuclei per high power field versus 1.7 ± 0.4, 25.7 ± 3.3 nuclei per high power field versus 3.2 ± 0.4 and 6.2 ± 0.3 μmol. hydroxyproline per gm. tissue versus 3.4 ± 0.1, respectively). Conversely daily administration of DHMEQ (8 mg./kg.) significantly inhibited nuclear factor κB activation and decreased mean tubular apoptosis (9.5 ± 2.1 nuclei per high power field), proliferation (10.2 ± 2.4 nuclei per high power field) and interstitial fibrosis (4.9 ± 0.4 μmol. hydroxyproline per gm. tissue) in the obstructed kidney. Conclusions: Specific inhibition of nuclear factor κB can prevent inflammatory renal responses, suggesting that targeting nuclear factor κB activation may be feasible for preventing inflammatory kidney diseases.
AB - Purpose: We determined whether the novel nuclear factor κB activation inhibitor dehydroxymethylepoxyquinomicin (DHMEQ), which is derived from epoxyquinomicin C, affects renal inflammatory responses in unilateral ureteral obstruction. Materials and Methods: DHMEQ (8 mg./kg.) was administered to rats 1 day after unilateral ureteral obstruction and every day thereafter. Kidneys were harvested at day 7 after unilateral ureteral obstruction. Tissue nuclear factor κB activity and transforming growth factor-β were determined by electrophoretic mobility shift assay and bioassay using mink lung epithelial cells, respectively. Renal tubular proliferation and apoptosis were detected by immunostaining proliferating cellular nuclear antigen and the TUNEL (Intergen, Purchase, New York) assay, respectively. Leukocyte infiltration was detected by immunostaining for CD45. Fibrosis was assessed by measuring tissue hydroxyproline content. Results: Unilateral ureteral obstruction for 7 days significantly activated nuclear factor κB, induced tubular apoptosis, proliferation and interstitial fibrosis in the obstructed kidney of the control group compared with their unobstructed counterparts (30.3 ± 4.5 nuclei per high power field versus 1.7 ± 0.4, 25.7 ± 3.3 nuclei per high power field versus 3.2 ± 0.4 and 6.2 ± 0.3 μmol. hydroxyproline per gm. tissue versus 3.4 ± 0.1, respectively). Conversely daily administration of DHMEQ (8 mg./kg.) significantly inhibited nuclear factor κB activation and decreased mean tubular apoptosis (9.5 ± 2.1 nuclei per high power field), proliferation (10.2 ± 2.4 nuclei per high power field) and interstitial fibrosis (4.9 ± 0.4 μmol. hydroxyproline per gm. tissue) in the obstructed kidney. Conclusions: Specific inhibition of nuclear factor κB can prevent inflammatory renal responses, suggesting that targeting nuclear factor κB activation may be feasible for preventing inflammatory kidney diseases.
KW - Apoptosis
KW - Inflammation
KW - Kidney
KW - Transcription factors
KW - Ureteral obstruction
UR - http://www.scopus.com/inward/record.url?scp=0037376397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037376397&partnerID=8YFLogxK
U2 - 10.1097/01.ju.0000045686.21766.c1
DO - 10.1097/01.ju.0000045686.21766.c1
M3 - Article
C2 - 12629415
AN - SCOPUS:0037376397
VL - 169
SP - 1559
EP - 1563
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
IS - 4
ER -